The Clinical Trial Gap in Africa
Africa bears nearly a quarter of the global burden of disease, yet the continent conducts only a sliver of the world's clinical trials and attracts less than two percent of global health research funding. This stark mismatch has long hindered the development of treatments tailored to African populations and delayed access to promising therapies for diseases that disproportionately affect the region.
In 2022, the World Health Assembly responded with Resolution 75.8, a landmark call for stronger clinical trial quality, coordination, and accountability worldwide. The resolution acknowledges that simply injecting more money into research infrastructure is not enough. What is needed, according to global health leaders, is a deliberate examination of the structural deficits that keep clinical research from flourishing in under-resourced settings.
The challenge is not merely financial. It is also procedural. In many African nations, would-be trial sponsors face overlapping, sequential reviews by ethics committees, institutional review boards, and regulatory authorities. These layers of oversight, while designed to protect participants, often create bottlenecks that slow trial approval and discourage investment. The question is not whether oversight matters; it is how to make that oversight work efficiently without sacrificing participant safety.
The TRACE Initiative: A Coordinated Response
Enter the TRACE initiative, short for Trial Regulation and Clinical Ethics Optimization. Operating across Rwanda, Tanzania, Nigeria, Zimbabwe, and Kenya, TRACE partners with national ethics committees, institutional review boards, and regulatory authorities in each country. Its goal is to identify the structural weaknesses that impede clinical trial readiness and to implement targeted fixes that yield measurable results.
According to a correspondence published in Nature Medicine by Kara L. Neil and Jeanine Condo on behalf of the TRACE Author Group, the initiative has already produced significant insights. Across all five countries, the interventions that generated the fastest and most tangible gains in trial readiness were not those that added technical capacity in isolation. Instead, the most effective approach was to coordinate ethics and regulatory review into a single, parallel process.
This finding runs counter to conventional wisdom. Many capacity-building efforts focus on training reviewers, purchasing software, or hiring more staff. While those elements are useful, TRACE discovered that the underlying structural issue is often the lack of alignment between the ethics and regulatory tracks. When these two review streams operate separately and sequentially, trial sponsors can lose months waiting for one body to finish before the other begins. By aligning them into a parallel workflow, TRACE countries shortened review timelines and made the overall process more predictable.
Why Parallel Review Works
The benefits of a coordinated review process extend beyond speed. When ethics committees and regulatory authorities work in parallel, they can share information and align requirements early. This reduces duplication of effort and minimizes the risk of conflicting recommendations. Sponsors receive clear, consistent guidance from the outset, which helps them design trials that meet both ethical and regulatory standards from the start.
Parallel review also builds trust among stakeholders. Investigators see that oversight bodies are not obstacles but partners in ensuring high-quality research. Participants and communities gain confidence that trials are being vetted thoroughly yet efficiently. And national health systems benefit from faster access to evidence that can inform policy and practice.
For African countries, where public health emergencies often demand rapid research responses, the ability to accelerate trial approval without compromising oversight is not a luxury; it is a necessity. The COVID-19 pandemic demonstrated that when regulatory systems are slow, the most vulnerable populations wait longer for vaccines and treatments. TRACE's early results suggest a pathway toward more resilient clinical trial ecosystems.
Lessons for the Global Community
The TRACE initiative offers lessons that extend well beyond the five participating nations. Its findings align with the World Health Organization's broader Global Action Plan for Clinical Trial Ecosystem Strengthening, which emphasizes coordination, quality, and accountability as core pillars.
One key lesson is that context matters. A one-size-fits-all approach to capacity building is unlikely to succeed. TRACE deliberately worked with each country's existing ethics and regulatory structures, adapting its model to local legal frameworks, resource levels, and cultural norms. This flexibility allowed the initiative to achieve buy-in from national authorities rather than imposing an external template.
A second lesson is the importance of measuring progress. TRACE did not rely on anecdotes or subjective impressions. It tracked timelines, documented process changes, and assessed trial readiness using consistent indicators. This data-driven approach enabled the initiative to identify which interventions had the greatest impact and to adjust course when needed.
A third lesson is that collaboration across borders can amplify national efforts. By bringing together representatives from Rwanda, Tanzania, Nigeria, Zimbabwe, and Kenya, TRACE created a community of practice where regulators and ethicists could share insights, troubleshoot common challenges, and benchmark their performance against peers. This regional perspective is especially valuable in Africa, where many countries have small research budgets and limited regulatory capacity.
The Road Ahead
While the early results are encouraging, the TRACE initiative is not complete. Sustained momentum will require continued political will, financial support, and technical assistance. The Gates Foundation has provided funding, and the initiative is careful to note that the conclusions and opinions expressed are those of the authors alone. But long-term success depends on embedding these reforms into national institutions so that they outlast any single project cycle.
For Africa to close the gap between disease burden and research output, it must address the structural inefficiencies that discourage trial investment. TRACE's experience suggests that coordinating ethics and regulatory review is a high-leverage intervention—one that delivers measurable gains quickly and lays the groundwork for deeper capacity building.
The global health community has long recognized the moral imperative of including African populations in clinical research. The TRACE initiative demonstrates a practical path forward. By fixing the first structural deficit—the fragmented review process—African nations can make themselves more attractive as trial destinations. That, in turn, can accelerate the development of treatments for diseases that disproportionately affect the continent and ensure that the benefits of medical innovation reach those who need them most.
Key Takeaways
- Africa carries about 25% of the global disease burden but performs only 2% of clinical trials.
- The TRACE initiative operates in Rwanda, Tanzania, Nigeria, Zimbabwe, and Kenya.
- Coordinating ethics and regulatory review into a single parallel process produced the fastest measurable gains in trial readiness.
- This approach cuts delays, reduces redundancy, and strengthens trust among investigators and communities.
- TRACE's model aligns with WHO Resolution 75.8 and the global action plan for clinical trial ecosystem strengthening.
The experience of TRACE is still evolving, but its early findings offer a clear message for policymakers, funders, and researchers: when it comes to building clinical trial capacity in Africa, coordination is not just a nice-to-have. It is often the most effective starting point.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
